The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 2, open-label study of rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation.
Susan M. Domchek
Research Funding - AbbVie; AstraZeneca; Clovis
Robert R. McWilliams
No relevant relationships to disclose
Andrew Eugene Hendifar
No relevant relationships to disclose
Rachna T. Shroff
No relevant relationships to disclose
Lawrence P. Leichman
Consultant or Advisory Role - Clovis
Ron Epelbaum
No relevant relationships to disclose
Ravit Geva
No relevant relationships to disclose
George P. Kim
Consultant or Advisory Role - Clovis
Steven R. Alberts
No relevant relationships to disclose
Robert A. Wolff
Consultant or Advisory Role - Clovis (U)
Andrew R. Allen
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Heidi Giordano
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Mitch Raponi
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Jeffrey D. Isaacson
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Lindsey Rolfe
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Andrew Biankin
Consultant or Advisory Role - Clovis
Robert H. Vonderheide
Research Funding - Pfizer; Roche